Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

The study adds to growing evidence that digital tools can maximize genetic counselors' limited time without patient harm.

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Sarepta is the first company to publicly disclose that it's received the designation, for which the FDA had issued a draft guidance last year.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

Within weeks of treating patients with CER-1236, the company hopes to start learning about its safety profile and gauge efficacy markers.

The partners further aim to raise awareness and increase early diagnosis of BAG3-associated dilated cardiomyopathy.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...